Sen. Bernie Sanders (I-Vt.) delivered a pointed critique of congressional influence from pharmaceutical companies during a Senate Health, Education, Labor, and Pensions Committee hearing on September 15, 2025. Addressing a room full of lawmakers and witnesses, Sanders remarked, “Everybody in this room took Big Pharma money. Are they all corrupt?” The statement, aimed at the pervasive role of industry donations in politics, underscored his long-standing push for drug price reforms amid soaring costs for Americans.
Sanders highlighted Federal Election Commission data showing over $100 million in pharmaceutical contributions to congressional campaigns in the 2024 cycle alone, with both parties receiving substantial sums. He accused the industry of “buying access” to block legislation like Medicare drug price negotiation, which could save taxpayers billions. The Vermont senator’s rhetoric drew applause from progressive allies but sharp rebukes from Republicans, who called it “class warfare” and defended donations as free speech.
The hearing focused on insulin pricing, where costs have quadrupled since 2000 despite stagnant innovation. Sanders cited cases like a diabetic mother forced to ration doses, arguing corporate greed trumps public health. Critics, including Sen. Bill Cassidy (R-La.), countered that innovation requires investment, and donations reflect broad support for medical advancement.
Sanders’ comments tap into growing public frustration, with a 2025 Gallup poll showing 70% of Americans view Big Pharma unfavorably. As Democrats eye midterms, his call for transparency—banning stock trading by lawmakers—gains momentum. Whether it leads to reform remains uncertain, but Sanders has reignited the debate on money’s sway in Washington.
